Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Novartis AG

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.

Outlook 2024 Commercial Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

Commercial Clinical Trials

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.

Strategy Sales & Earnings

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Research & Development Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Admune Therapeutics
    • Amblyotech, Inc.
    • Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
    • Aspen Japan K.K.
    • Biocine
    • CELLforCURE SASU
    • Chiron Corporation
    • CIBA-GEIGY
    • Corthera Inc.
    • CoStim Pharmaceuticals Inc.
    • ESBATech AG
    • Fougera Pharmaceuticals, Inc.
    • Gyroscope Therapeutics Limited
    • Hexal AG
    • Lek Pharmaceuticals, Inc.
    • Matrix Pharmaceuticals
    • NeuTec Pharma
    • Novartis Groupe France S.A.
    • Novartis Pharmaceuticals
    • Novartis Oncology
    • Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
    • PowerVision, Inc.
    • Protez Pharmaceuticals
    • Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
    • Ebewe Pharma)
    • Selexys Pharmaceuticals Corporation
    • Speedel Holding
    • Spinifex Pharmaceuticals Pty. Ltd.
    • Transcend Medical, Inc.
    • Encore Vision, Inc.
    • Ziarco Group Limited
    • AveXis, Inc.
    • BioLife Cell Bank, Inc.
    • Endocyte, Inc.
    • IFM Tre
    • Zyma SA
    • Annovation Biopharma, Inc.
    • Boxford Subsidiary
    • Curacyte Discovery GmbH
    • Incline Therapeutics, Inc.
    • ProFibrix B.V.
    • Rempex Pharmaceuticals, Inc.
    • Targanta Therapeutics Corporation
    • Tenaxis Medical
    • The Medicines Company
    • Novartis Gene Therapies
UsernamePublicRestriction

Register